Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration
In one of our studies published in Nature Communications, we discover Nb457, an alpaca-derived nanobody with broad-spectrum anti-HIV-1 activity. Nb457 induces conformational changes in CD4, blocking viral entry. Its trimeric form achieves complete HIV-1 inhibition, promising treatments.
